- Home
- WFC vs NVO Comparison
WFC vs NVO Comparison
Compare WFC & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WFC | NVO |
|---|---|---|
| Founded | 1852 | 1923 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 290.6B | 269.6B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | WFC | NVO |
|---|---|---|
| Price | $87.98 | $63.87 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 16 | 10 |
| Target Price | ★ $95.97 | $54.25 |
| AVG Volume (30 Days) | 14.7M | ★ 21.4M |
| Earning Date | 01-14-2026 | 02-04-2026 |
| Dividend Yield | ★ 2.07% | 1.98% |
| EPS Growth | ★ 16.57 | 10.06 |
| EPS | ★ 6.26 | 3.67 |
| Revenue | ★ $80,041,000,000.00 | $49,580,393,058.00 |
| Revenue This Year | $11.84 | $7.25 |
| Revenue Next Year | $4.42 | $0.24 |
| P/E Ratio | ★ $13.89 | $16.99 |
| Revenue Growth | 2.67 | ★ 16.64 |
| 52 Week Low | $58.42 | $43.08 |
| 52 Week High | $97.76 | $93.80 |
Technical Indicators
Market Signals| Indicator | WFC | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 41.03 | 70.40 |
| Support Level | $86.03 | $57.56 |
| Resistance Level | $89.00 | $64.16 |
| Average True Range (ATR) | 1.86 | 1.78 |
| MACD | -0.91 | 0.41 |
| Stochastic Oscillator | 18.46 | 96.44 |
Price Performance
Historical ComparisonAbout WFC Wells Fargo & Company
Wells Fargo is one of the largest banks in the United States, with approximately $2.0 trillion in balance-sheet assets. The company has four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the US market.
About NVO Novo Nordisk A/S
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.